Focused on restoring gut health
We are developing an innovative advanced microbiome therapeutic to address liver diseases and Irritable Bowel Syndrome (IBS).
In chronic liver disease and IBS, an imbalanced microbiome and damaged gut wall allow inflammatory molecules to leak into the bloodstream leading to serious health issues.
Potential to address significant unmet needs
Our solution, a gut-restricted oral adsorbent (YAQ001), is designed to adsorb endotoxins and interfere with the growth of harmful pathogenic bacteria without killing beneficial microbes, thus restoring the microbiome.